So after about 3 months out of treatment i did 2 more rounds of chemo, then i did another 8 color flow cytometry which was positive again, i stayed another 3 months out of treatment and then i received a stem cell transplant.
My question is - The breaks out of treatment that i decided to have is it possible to affect me negative in the future? My main point was that when i was out of treatment i had the risk of relapse but at the same time because i didn't had continuous treatment the disease wasn't becoming resistant to the treatment because of additional clones as a result of the continuous chemo.
Best regards and good luck
Any advice provided in these postings is based on a very limited amount of information. There is no substitute for the care of your oncologist/hematologist. Therefore, all suggestions should be discussed with your treating physician. None of the comments presented here are meant to replace the evaluation of a patient by a knowledgeable physician.
Dr. Jason Valent
- Name: Jason Valent, M.D.
Beacon Medical Advisor
Revlimid Maintenance After Stem Cell Transplantation
For second place, the surveyed physicians chose two Phase 3 studies that show Revlimid maintenance therapy following stem cell transplantation doubles progression-free survival. There was some disagreement among the physicians, though, about whether the results demonstrate that Revlimid maintenance has a significant overall survival benefit.
“These two papers show that low-dose Revlimid maintenance can double the length of disease response after autologous [stem cell] transplant,” said Dr. William Bensinger from the Fred Hutchinson Cancer Research Center. “They also show that [Revlimid maintenance is associated with] more episodes of neutropenia [low white blood cell counts] and infection and also increases the risk of second primary cancers.”
Dr. Edward Libby also from the Fred Hutchinson Cancer Research Center added, “These two articles confirm the significant improvement seen in progression-free survival after transplant but were unable to show improvements in overall survival.”
“Both trials confirm that single-agent Revlimid after autologous stem cell transplant doubles the progression-free survival as compared with placebo. This finding is very important,” said Dr. Mateos. “Although no significant benefit has been observed in overall survival in the French trial, the advantage in progression-free survival is of great value.”
Dr. Heinz Ludwig from Wilhelminenspital in Vienna, Austria, on the other hand, believes Revlimid maintenance therapy will provide an overall survival benefit to certain myeloma patients in both studies. “Doubling progression-free survival is unprecedented, and overall survival is already superior in the CALGB study. With further follow-up a survival advantage should also become evident in the good-risk patients of the other study.”
For more information, see the CALGB and French studies in the New England Journal of Medicine, the related Beacon news, and all Beacon articles about maintenance therapy.
Hope this helps and God Bless
- Name: George Jurak
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: Jan. 2011
- Age at diagnosis: 59